Slingshot members are tracking this event:
Merck (MRK) Announces Phase 3 KEYNOTE-045 Results Evaluating Keytruda in Advanced Urothelial Cancer
Slingshot Insights Explained
Oct 21, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 3, Keynote-045, Keytruda, Advanced Urothelial Cancer, Bladder Cancer